3.6% of economic rights, 1.8% of voting rights*
Institut Mérieux, an independent family-owned company from over a century, is dedicated to the fight against infectious diseases and cancers, with a global and long-term vision. Thanks to five companies – bioMérieux, Transgene, ABL, Mérieux NutriSciences and Mérieux Equity Partners – Institut Mérieux develops complementary approaches to meet today’s public health challenges: from prevention of health risks to innovative disease treatment, including the key step of diagnosis.
* Percentages as of 31 August 2023. Latest financial year data at 31 December 2022.